Opdivo (nivolumab) Market Research Report 2025: Epidemiology, Pipeline Analysis, Insights & Forecasts 2019-2034 - ResearchAndMarkets.com

The "Opdivo (nivolumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.

The Opdivo (Nivolumab) market report provides a comprehensive analysis of key market dynamics, covering its size, growth potential, and segmentation across major regions and countries. It reveals past trends and future growth projections, examining the competitive landscape, market share, trends, and strategic developments.

Historically, market growth has been driven by an increased prevalence of cancer, substantial R&D investments, and rising expenditure on healthcare facilities. Specifically, a significant rise in non-small cell lung cancer (NSCLC) cases has been a vital growth driver. In 2024, the U.S. reported 234,580 new lung cancer cases, with 80% being NSCLC. Opdivo enhances the immune response by blocking the PD-1 receptor on immune cells, aiding in the attack on cancer cells.

The forecast period anticipates growth fueled by the acceptance of immunotherapy, increased healthcare spending, diversified uses of nivolumab, and a preference for advanced treatment options. Notable trends include product innovation, geographic expansion, enhanced personalized medicine practices, and ongoing cancer research advancements.

A surge in the development of combination therapies is set to enhance treatment efficacy and expand applicability across various cancer types. These strategies, which address resistance mechanisms, provide more comprehensive cancer treatment alternatives. In October 2024, the FDA approved Opdivo in combination with platinum-doublet chemotherapy for resectable NSCLC, facilitating its pre- and post-surgery application.

The market has also witnessed strategic partnerships, such as the collaboration between Lyvgen Biopharma and Bristol Myers Squibb (BMS) in November 2022. This partnership aims at a Phase II clinical trial to assess LVGN7409 with Opdivo for advanced NSCLC.

Key players in the market include Bristol-Myers Squibb and Ono Pharmaceutical. Regionally, North America led in terms of market size in 2024, but Asia-Pacific is projected to grow fastest. The report covers several regions including Asia-Pacific, Western and Eastern Europe, North America, South America, and the Middle East and Africa. Key countries included are the USA, China, Germany, Japan, and others.

Opdivo formulations are available in various dosages, such as 40 mg/4 ml, 100 mg/10 ml, and 240 mg/24 ml, typically administered as injections or solutions for diverse patient needs. This immunotherapy targets numerous cancers, including melanoma, NSCLC, and others, with end-users primarily comprising hospitals and clinics.

This report is part of a series providing global market statistics for Opdivo, detailing market segments, trends, and opportunities for growth in this specific industry. It focuses on both monotherapy and combination therapies, with sales figures reflecting factory gate values.

Key Highlights:

• Embrace a global perspective by accessing the most comprehensive report covering ten geographies.
• Evaluate the impact of macro factors such as global conflicts, pandemics, economic recovery, inflation, and interest rate changes.
• Formulate regional and country-specific strategies based on local data and analysis.
• Discover growth segments for strategic investments.
• Leverage forecast data and market drivers to outperform competitors.
• Gain insights into market shares for a deeper understanding of customer dynamics.
• Benchmark organizational performance against key competitors.
• Utilize report data to enhance both internal and external presentations with high-quality analysis.
• Receive the report updated with the latest data, including an Excel data sheet for easy extraction and analysis.
• Access data through an Excel dashboard for interactive insights.

Key Topics Covered:

1. Executive Summary

2. Opdivo (Nivolumab) Market Characteristics

3. Opdivo (Nivolumab) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route of Administration (ROA)
• 3.3. Mechanism of Action (MOA)
• 3.4. Safety and Efficacy

4. Opdivo (Nivolumab) Market Trends and Strategies

5. Opdivo (Nivolumab) Market - Macro Economic Scenario

6. Global Opdivo (Nivolumab) Growth Analysis and Strategic Analysis Framework

• 6.1. Global Opdivo (Nivolumab) PESTEL Analysis
• 6.2. Analysis of End Use Industries
• 6.3. Global Opdivo (Nivolumab) Market Growth Rate Analysis
• 6.4. Global Opdivo (Nivolumab) Historic Market Size and Growth
• 6.5. Global Opdivo (Nivolumab) Forecast Market Size and Growth
• 6.6. Global Opdivo (Nivolumab) Total Addressable Market (TAM)

7. Global Opdivo (Nivolumab) Market Pricing Analysis & Forecasts

8. Opdivo (Nivolumab) Market Segmentation

• 8.1. Global Opdivo (Nivolumab) Market, Segmentation by Type
• 8.2. Global Opdivo (Nivolumab) Market, Segmentation by Dosage
• 8.3. Global Opdivo (Nivolumab) Market, Segmentation by Demographic
• 8.4. Global Opdivo (Nivolumab) Market, Segmentation by Application
• 8.5. Global Opdivo (Nivolumab) Market, Segmentation by End-User

9. Global Opdivo (Nivolumab) Market Epidemiology of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence and Prevalence of Clinical Indications

10. Opdivo (Nivolumab) Market Regional and Country Analysis

• 10.1. Global Opdivo (Nivolumab) Market, Split by Region
• 10.2. Global Opdivo (Nivolumab) Market, Split by Country

For more information about this report visit https://www.researchandmarkets.com/r/kc4asv

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250514493082/en/